Clinical trials: sponsored by Fujian Cancer Hospital
Radiation Injuries, Rectal Diseases
Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury
The main objective of this study was to evaluate the efficacy and safety of drug retention enema for the prevention of acute radiation rectal injury in the real world.
- Trial name
- NCT06325982
- Testing
- Triethanolamine cream
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Leptomeningeal Metastasis
Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI
We aim to compare the efficacy and safety of double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus double Dose of Third-generation EGFR-TKI in patients with leptomeningeal progression following the treatment…
- Trial name
- NCT06441045
- Testing
- Double Dose of Third-generation EGFR-TKI, Intrathecal Pemetrexed
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Fujian Cancer Hospital
Immunotherapy Gastroesophageal Junction
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
To evaluate the efficacy and safety of tislelizumab combined with antilotinib and SOX regimen for neoadjuvant treatment of locally advanced esophagogastric junction cancer
- Trial name
- NCT06396585
- Testing
- Tislelizumab, Anlotinib, Oxaliplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Fujian Cancer Hospital
Immunotherapy Gastrict Cancer
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1 Vs oxaliplatin plus S1.
- Trial name
- NCT05699655
- Testing
- Tislelizumab, apatinib, oxaliplatin
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Fujian Cancer Hospital
Stage IIIA Hepatocellular Carcinoma
Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma
The purpose of this clinical research study is to investigate the efficacy and safety of Radiotherapy Combined with TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma with Portal Vein Tumor Thrombus(PVTT).
- Trial name
- NCT06061445
- Testing
- Radiotherapy combined with TKI and Anti-PD-1 Antibody
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic…
- Trial name
- NCT06331845
- Testing
- Gemcitabine, Cisplatin, Paclitaxel protein-bound
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Carcinoma, Cervix Carcinoma
Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin
This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.
- Trial name
- NCT05910177
- Testing
- Karelizumab combined with etoposide and cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
EGFR/ ALK-negative Advanced NSCLC
Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC
To evaluate the efficacy of metronomic chemotherapy combination with tislelizumab in EGFR/ALK-negative advanced NSCLC patients intolerant to first-line standard chemotherapy.
- Trial name
- NCT06260553
- Testing
- tislelizumab and metronomic oral vinorelbine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Cancer Hospital
Ovarian Neoplasms, Ovarian Diseases
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
This is a single-arm, exploratory study. People with recurrent platinum-resistant ovarian cancer who have not received any previous systemic antitumor therapy for ovarian cancer were selected to evaluate the efficacy and safety…
- Trial name
- NCT05753826
- Testing
- Adebrelimab, Fuzuloparib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital
Ovarian Neoplasms
The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment.
- Trial name
- NCT06242392
- Testing
- homologous recombination deficiency
- Volunteers
- 250 people
- Sponsor
- Fujian Cancer Hospital
Endometrial Cancer, Endometrial Adenocarcinoma
Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with chemotherapy in patients with recurrent or advanced endometrial cancer.
- Trial name
- NCT06066216
- Testing
- Cadonilimab, Carboplatin, Cisplatin
- Volunteers
- 45 people
- Sponsor
- Fujian Cancer Hospital
Colo-rectal Cancer
A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases
To explore the Efficacy and Safety of Tislelizumab combined with fruquintinib and Chidamide in the treatment of unresectable or advanced microsatellite stabilized (MSS/pMMR) colorectal cancer with liver metastases
- Trial name
- NCT06218888
- Testing
- Tislelizumab, Fruquintinib, Chidamide
- Volunteers
- 17 people
- Sponsor
- Fujian Cancer Hospital
EGFR Positive Non-small Cell Lung Cancer
SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)
This is a single-arm, sequential study assessing the efficacy and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced non-small cell lung cancer (NSCLC) : first-line treatment or failed…
- Trial name
- NCT06208033
- Testing
- SMET12
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
This study is a single center, phase II study, to evaluate the effectiveness and safety of PD-1 Antibody(Tislelizumab) Plus Irinotecan Combined With POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the…
- Trial name
- NCT06197438
- Testing
- Tislelizumab, Oxaliplatin, Levo-Leucovorin
- Volunteers
- 36 people
- Sponsor
- Fujian Cancer Hospital
Cervical Cancer, Radiotherapy
MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy
This study aims to validate the value of tumor involvement features based on MRI in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles…
- Conditions
- Cervical Cancer, Radiotherapy, Prognostic Model, MRI
- Trial name
- NCT06197126
- Testing
- Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Cervical Cancer
Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer
Prospective single-arm clinical study of adebrelimab combined with concurrent chemoradiotherapy in locally advanced cervical cancer
- Trial name
- NCT06149767
- Testing
- Adebrelimab
- Volunteers
- 26 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life
Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer. The last three decades of research in head and neck radiation oncology have largely focused on improvements in survival, which have mostly come at the cost of long…
- Trial name
- NCT06136962
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Fujian Cancer Hospital
Untreated Advanced Non-small Cell Lung Cancer
Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer
This is a single-arm, single-centre phase II study to evaluate the efficacy (PFS, ORR, DCR) and safety of recombinant human adenovirus type 5 in combination with tirelizumab and platinum-containing dual-agent chemotherapy in…
- Trial name
- NCT06136910
- Testing
- Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer
Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors.
- Trial name
- NCT05839470
- Testing
- cadonilimab, irinotecan, Oxaliplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Endometrial Neoplasms
MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer
Molecular typing provides accurate information for the diagnosis, treatment and prognosis prediction of endometrial cancer, which has important clinical significance.
- Trial name
- NCT06126393
- Testing
- next generation sequencing AND Immunohistochemical examination
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Fujian Cancer Hospital